Genome-wide target specificities of CRISPR-Cas9 nucleases revealed by multiplex Digenome-seq by Kim, Daesik et al.
Genome-wide target specificities of CRISPR-Cas9
nucleases revealed by multiplex Digenome-seq
Daesik Kim,1,2 Sojung Kim,1,2 Sunghyun Kim,1 Jeongbin Park,3 and Jin-Soo Kim1,2
1Center for Genome Engineering, Institute for Basic Science, Seoul 151-747, South Korea; 2Department of Chemistry, Seoul National
University, Seoul 151-747, South Korea; 3Department of Chemistry, Hanyang University, Seoul 133-791, South Korea
We present multiplex Digenome-seq to profile genome-wide specificities of up to 11 CRISPR-Cas9 nucleases simultaneously,
saving time and reducing cost. Cell-free human genomic DNAwas digested using multiple sgRNAs combined with the Cas9
protein and then subjected to whole-genome sequencing. In vitro cleavage patterns, characteristic of on- and off-target sites,
were computationally identified across the genome using a new DNA cleavage scoring system. We found that many false-
positive, bulge-type off-target sites were cleaved by sgRNAs transcribed from an oligonucleotide duplex but not by those
transcribed from a plasmid template. Multiplex Digenome-seq captured many bona fide off-target sites, missed by other
genome-wide methods, at which indels were induced at frequencies <0.1%. After analyzing 964 sites cleaved in vitro by
these sgRNAs and measuring indel frequencies at hundreds of off-target sites in cells, we propose a guideline for the choice
of target sites for minimizing CRISPR-Cas9 off-target effects in the human genome.
[Supplemental material is available for this article.]
RNA-guided endonucleases (RGENs), derived from the type II
CRISPR (clustered regularly interspaced repeat)-CRISPR–associated
(Cas) prokaryotic adaptive immune system, enable genome edit-
ing in cultured cells and whole organisms (Cho et al. 2013a,b;
Cong et al. 2013; Hwang et al. 2013; Jiang et al. 2013; Jinek et al.
2013;Mali et al. 2013b; Kim and Kim 2014). These nucleases, how-
ever, can induce off-target mutations, limiting their utility in re-
search and medicine (Cradick et al. 2013; Fu et al. 2013; Hsu
et al. 2013; Pattanayak et al. 2013; Cho et al. 2014). Recently, we
and other groups independently presented several different meth-
ods for profiling genome-wide specificities of RGENs, which con-
sist of gRNAs and the Cas9 protein originated from Streptococcus
pyogenes, in human cells (Frock et al. 2015; Kim et al. 2015; Ran
et al. 2015; Tsai et al. 2015;Wang et al. 2015). All of thesemethods
rely on high-throughput sequencing of human genomic DNA that
is cleaved by RGENs in cells or in vitro. High-throughput, genome-
wide translocation sequencing (HTGTS) is based on translocations
induced by nonhomologous end-joining (NHEJ) repair of two con-
current DNA double-strand breaks (DSBs) in cells (Frock et al.
2015). Both genome-wide, unbiased identification of DSBs en-
abled by sequencing (GUIDE-seq) (Tsai et al. 2015) and integra-
tion-deficient lentiviral vector (IDLV) capture (Wang et al. 2015)
rely onNHEJ-mediated insertions of small duplex oligonucleotides
or lentiviral vectors, respectively, at cleavage sites. Direct in situ
breaks labeling, enrichment on streptavidin, and next-generation
sequencing (BLESS) is a method of capturing DSBs in fixed cells
(Crosetto et al. 2013; Ran et al. 2015). Digenome-seq (digested
genome sequencing) relies on whole-genome sequencing (WGS)
of cell-free genomic DNA digested in vitro using a nuclease of
interest (Kim et al. 2015). Although each of thesemethods has suc-
cessfully identified genome-wide off-target sites in human cells,
it is unknown how comprehensive and sensitive each method is:
Only one gRNA was analyzed by three different methods thus far
(Gabriel et al. 2015; Kim et al. 2015).
In this study, we performed multiplex Digenome-seq to pro-
file genome-wide specificities of up to 11 CRISPR-Cas9 nucleases
at once. Multiplex Digenome-seq was more comprehensive than
other methods, revealing many bona fide off-target sites that had
been missed by GUIDE-seq or HTGTS. After analyzing hundreds
of off-target sites,we found a rule of thumb for choosing target sites
to minimize genome-wide off-target effects of CRISPR-Cas9.
Results
Improving Digenome-seq
First, we developed a scoring system to computationally identify in
vitro cleavage sites across the human genome using WGS data.
Although our original Digenome-seq analysis was highly repro-
ducible, some sites with heterogeneous cleavage patterns or with
a low sequencing depth were often missed. We found that these
sites could be identified by assuming that Cas9 can produce 1- or
2-nucleotide (nt) overhangs in addition to blunt ends. We as-
signed a DNA cleavage score to each nucleotide position, based
on patterns of alignments of sequence reads (Supplemental Fig.
1; Supplemental Scripts 1). Our improved program successfully
captured many additional sites that had been missed previously.
A genome-wide plot of cleavage scores showed that false-positive
sites obtained with undigested genomic DNA were still extremely
rare (Fig. 1A): A few false-positive sites identified in the entire ge-
nome contained naturally occurring indels in the genomic DNA
and could be filtered out with ease. Sequence reads around natural-
ly occurring indel sites cannot be mapped properly, often produc-
ing false-positive sites. As shown by two independent Digenome-
seq analyses, cleavage scores across the human genomewere high-
ly reproducible (R2 = 0.89) (Supplemental Fig. 2).
We also found that sgRNAs transcribed using a plasmid tem-
plate in a Digenome-seq analysis did not cleave any of the false-
positive, bulge-type off-target sites, with a missing nucleotide
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comparedto theon-target site (Linetal.2014),whichwerecaptured
with those transcribed using an oligonucleotide duplex (Fig. 1B;
Supplemental Fig. 3). Apparently, the latter sgRNAswere heteroge-
neous, containing truncatedmolecules transcribed fromsynthesis-
failed oligonucleotides. As a result, cleavage sites identified using
sgRNAs transcribed from a plasmid template were more highly ho-
mologous to its on-target site than those identified using sgRNAs
transcribed from an oligonucleotide template (Supplemental
Table 1), as shown by sequence logos obtained computationally
by comparing DNA sequences around cleavage sites (Fig. 1C).
Thus, the use of a new cleavage scoring system and sgRNAs tran-
scribed from plasmid templates substantially reduced the number
of false-negative sites and false-positive sites, respectively.
Multiplex Digenome-seq
Unlike other methods, Digenome-seq can be multiplexed without
increasing sequencing depth proportionally to the number of nu-
cleases. We chose 10 sgRNAs that had been analyzed individually
using GUIDE-seq (Tsai et al. 2015), which is likely to be more sen-
sitive than IDLV capture and other methods. Note that BLESS cap-
tures a snapshot of DSBs at a given moment of cell fixation
(Crosetto et al. 2013) and that HTGTS relies on two concurrent
DSBs, rather than one, induced in a single cell (Chiarle et al.
2011). We digested human genomic DNA with a mixture of the
Cas9 protein, the 10 sgRNAs, and one additional sgRNA targeted
to the HBB gene, which we had analyzed in our previous study
(Kim et al. 2015), and carried out two independent WGS analyses
(Fig. 2A). Genome-wide in vitro cleavage sites were identified com-
putationally using the scoring system. A total of 964 sites were
found in the human genome (Supplemental Table 2). All of these
siteswere then classified computationally according to the edit dis-
tance from the on-target sites (Fig. 2A; Supplemental Table 2;
Supplemental Scripts 2), which ranged from zero (on-target sites)
to 10. The mean edit distance was 14.4, which is the average edit
distance between any two on-target sites among the 11 on-target
sites. We recommend choosing on-target sites that differ from
each other by at least 11 nt in a multiplex Digenome-seq analysis,
to facilitate classification of cleavage sites by edit distance.
Unlike GUIDE-seq and other methods, which require a filter-
ing step to discard up to 90%of captured sites with poor homology
to on-target sites, multiplex Digenome-seq does not filter sites and
sorts sites based on edit distance. Yet, the 964 sites were divided
into 11 groups unambiguously. Furthermore, each of the 11
groups of in vitro cleavage sites was highly homologous to one
of the 11 on-target sequences. Thus, de novo motifs or sequence
logos obtained by comparing sequences in each group showed
matches with respective target sequences at almost every nucleo-
tide position (Fig. 2A). This result suggests that the 5′-terminal
10-nt region in a 23-nt target sequence contributes to the specific-
ity of RGENs, albeit to a lesser extent than do the protospacer-ad-
jacent motif (PAM), recognized by Cas9, and the PAM-proximal
Figure 1. Improving Digenome-seq analysis. (A) Genome-wide Circos plots of in vitro DNA cleavage scores. Human genomic DNA (red) or RGEN-digest-
ed genomic DNA (green) was subjected to whole-genome sequencing. The few false-positive sites found in intact genomic DNA are not visible because
their cleavage scores are not high. (B) Schematic overview of Digenome-seq using sgRNA transcribed from an oligonucleotide duplex or a plasmid. (C)
Sequence logos of cleavage sites obtained using sgRNA transcribed from an oligonucleotide duplex or a plasmid.
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10-nt “seed” region (Jinek et al. 2012; Cong et al. 2013; Pattanayak
et al. 2013).We noted that all but one of the 964 sites cleaved by 11
RGENs contained a PAM or PAM-like sequence, that is, 5′-NGG-3′
or 5′-NNG-3′/5′-NGN-3′, respectively, 3 nt downstream from
cleavage positions, confirming that DSB ends produced in vitro
cannot be trimmed by endogenous DNA repair systems, unlike
DSBs induced in cells. Thus, in vitro cleavage sites can be pinpoint-
ed without a computational search for homologous sequences, a
feature not shared with GUIDE-seq and HTGTS.
First, we checked whether an sgRNA in a pool can cleave its
on-target and off-target sites. Seventeen out of 30 (57%) sites
that were cleaved using the single HBB-specific sgRNA alone at
high concentration (900 nM) plus Cas9 (300 nM) were also cap-
tured by multiplex Digenome-seq using the same sgRNA at low
concentration (82 nM) (Fig. 2B,C). Note that more sites are cap-
tured at higher concentration of sgRNAs (Kim et al. 2015).
Importantly, all four off-target sites and the on-target site that
had been validated using targeted deep sequencing in our previous
study (Kim et al. 2015) were identified by multiplex Digenome-
seq. This result suggests that each sgRNA in a pool of up to
11 sgRNAs can guide Cas9 to most of its on-target and off-target
sites independently from each other, supporting the basis of
multiplexing.
In vitro cleavage sites
The 11 sgRNAs showed a wide spectrum of genome-wide specific-
ities: The number of cleavage sites per sgRNA in the human ge-
nome ranged from 13 to 302 (Fig. 3A; Supplemental Table 2). As
expected, all of the 11 on-target sites and most of the sites with
one or two mismatches (but with no DNA or RNA bulge), identi-
fied in the human genome using Cas-OFFinder (Bae et al. 2014),
were captured by Digenome-seq (Fig. 3B). However, sites with
more than three mismatches were rarely captured. The fraction
of Digenome-captured sites decreased exponentially as the num-
ber of mismatches increased from three to six (Fig. 3B). We also
found that sites with two or more mismatches in the seed region
were much less likely to be cleaved in vitro than those with zero
or one mismatch in the seed (P < 0.01, Student’s t-test). Out of
the 964 sites cleaved in vitro using the 11 sgRNAs transcribed
fromplasmid templates, only a single site had amissingnucleotide
(an RNA bulge) compared with the on-target site.
Interestingly, we found a strong correlation (R2 = 0.93) be-
tween the number of Digenome-captured sites and the number
of homologous sites with six or fewer nucleotide mismatches in
the human genome (defined as “orthogonality” in Tsai et al.
2015) (Fig. 3C). The six sgRNAs with fewer than 13,000 such ho-
mologous sites in the human genome were much more specific
Figure 2. Multiplex Digenome-seq. (A) Schematic overview of multiplex Digenome-seq. (B) A Venn diagram showing the number of in vitro cleavage
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(P < 0.01, Student’s t-test), cleaving 46 or fewer sites in vitro (28
sites/sgRNA, on average), than the other five sgRNAs with more
than 16,000 such sites, cleaving 63 or more sites in vitro (161
sites/sgRNA, on average) (Fig. 3C). This result is seemingly in con-
trast with the poor correlation (R2 = 0.29) observed between the
number of GUIDE-seq–positive sites and the orthogonality of the
target site relative to the human genome (Supplemental Fig. 4;
Tsai et al. 2015). The VEGFA2 site was an outlier, at least partially
causing the poor correlation. We noted, however, that the five
most specific sgRNAs revealed by GUIDE-seq, cleaving 10 or fewer
sites in cells, were coincident with the most specific sgRNAs re-
vealed by Digenome-seq.
Figure 3. Analysis of multiplex Digenome-captured sites. (A) Venn diagrams showing the number of sites captured by Digenome-seq, GUIDE-seq, and
HTGTS. (B) Fractions of sites captured by Digenome-seq according to the total mismatch number (top) and the mismatch number in the seed region (bot-
tom). (C, top) Scatterplot of the number of sites with six or fewer mismatches in the human genome versus the number of Digenome-captured sites.
(Bottom) Eleven RGEN target sites were divided into two groups, G1 and G2 (those with fewer than 13,000 and 16,000 sites, respectively, harboring
six or fewer mismatches in the human genome). Error bars, SEM. The P-value was calculated by Student’s t-test. (D) Scatterplot of the number of
GUIDE-seq captured sites versus the number of Digenome-seq captured sites.
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Digenome-seq vs. other methods
On average, multiplex Digenome-seq successfully identified 80
± 8% of sites captured previously by GUIDE-seq (Fig. 3A). For ex-
ample, all of the GUIDE-captured sites using the three sgRNAs spe-
cific to the VEGFA1, RNF2, and HEK293-3 sites were identified by
Digenome-seq. In addition, multiplex Digenome-seq captured a
total of 703 new sites (70 sites per sgRNA, on average) that had
been missed by GUIDE-seq (Fig. 3A). As a result, GUIDE-seq had
captured 25 ± 6% of sites identified by multiplex Digenome-seq.
The RNF2-specific sgRNA was a striking example. Two indepen-
dentGUIDE-seq analyses had failed to capture any single off-target
site, whereas Digenome-seq identified 12 cleavage sites in addi-
tion to the on-target site. In fact, we observed a poor correlation
(R2 = 0.20) between the number of Digenome-positive sites and
that of GUIDE-positive sites (Fig. 3D). It is likely that many addi-
tional sites that are cleaved in vitro and, thereby, captured byDige-
nome-seq are not accessible in cells.
Digenome-seq yielded more candidate off-target sites than
GUIDE-seq for nine out of 10 sgRNAs but still was not comprehen-
sive. (TheHBB sgRNAhadnot been analyzed byGUIDE-seq.) Thus,
in aggregate, GUIDE-seq had captured a total of 168 sites that were
missed byDigenome-seq. Two sgRNAs targeted to theVEGFA1 and
EMX1 sites had also been analyzed by HTGTS (Fig. 3A). Most sites
(31 out of 40 sites forVEGFA1 and 17 out of 19 sites for EMX1) cap-
tured by at least one of the other twomethods were also identified
by Digenome-seq, but it missed nine and two sites, respectively. It
is possible that some of these sites were false positives that resulted
from PCR primer–dependent artifacts or naturally occurring DSBs,
intrinsic limitations of GUIDE-seq and HTGTS. Many of these
sites, especially the two EMX1 off-target sites commonly identified
by the other two methods, however, would have been missed by
multiplex Digenome-seq, owing to a low sequencing depth at
these particular sites (Supplemental Fig. 5) or the low concentra-
tion (82 nM) of the sgRNA used in this study. These problems
could be alleviated by performing WGS at a higher sequencing
depth or by using a higher concentration of the sgRNA in a mono-
plex analysis, respectively.
The VEGFA2-specific sgRNA was the only exception to the
rule that Digenome-seq captures more candidate sites than
GUIDE-seq. Thus, GUIDE-seq had identified 122 sites that were
missed by Digenome-seq. The target sequence was unusual, con-
sisting of a stretch of cytosines. Many sequence reads, obtained
byWGS, at homopolymer sites can be discarded by amapping pro-
gram. GUIDE-seq may still capture these sites because PCR is used
to amplify oligonucleotide-captured sites.
We also compared cleavage sites identified in this study with
those captured by chromatin immunoprecipitation sequencing
(ChIP-seq) using catalytically dead Cas9 (dCas9) (Kuscu et al.
2014). Strikingly, a vast majority of Cas9-cleaved sites (288 sites,
98%) identified by Digenome-seq were not bound by dCas9
(Supplemental Fig. 6). This result suggests that DNA binding by
Cas9 is uncoupled from DNA cleavage and that ChIP-seq using
dCas9 is inappropriate for assessing genome-wide specificities of
Cas9 RGENs (Tsai et al. 2015), although it may still be useful for
profiling the specificities of dCas9-based transcription factors
and epigenome regulators.
Validation of off-target sites in cells
We then investigated, using a next-generation sequencing (NGS)
platform, whether each sgRNA plus Cas9 could induce off-target
indels in HeLa cells at some of these Digenome-captured and
GUIDE-captured sites (Table 1; Supplemental Table 3). We chose
candidate off-target sites with a fewer mismatches, irrespective of
DNA cleavage scores in this analysis. Indels were detected
over background noise levels caused by sequencing errors at 116
out of 132 (88%) sites commonly captured using Digenome-seq
and GUIDE-seq. In contrast, many of the sites captured by
Digenome-seq alone and GUIDE-seq alone were not validated by
targeted deep sequencing. Indels were induced above noise levels
at 21 out of 127 (17%) sites captured by Digenome-seq alone and
at 23 out of 45 (51%) sites captured by GUIDE-seq alone, confirm-
ing that neither of the twomethodswas comprehensive. Thus, the
overall validation rate was 53% [(21 + 116)/(127 + 132)], with
Digenome-seq, or 79% [(23 + 116)/(45 + 132)], with GUIDE-seq.
Indel frequencies at most of these validated sites were <1%,
much lower than those at respective on-target sites. For example,
the RNF2-targeted sgRNA induced indels at the on-target site and
two off-target sites identified in this study with a frequency of
68%, 0.25%, and 0.09%, respectively (Supplemental Fig. 7). It still
is possible that indels could be induced at NGS-invalidated sites
with frequencies below noise levels (0.001%–4%, depending on
the site).
Next, we investigated whether off-target sites validated in
HeLa cells in this study had beenmissed by GUIDE-seq performed
in U2OS cells or HEK 293T cells, owing to the differential chroma-
tin states. We chose five validated sites that were identified using
four sgRNAs in this study but had been missed by GUIDE-seq.
Indels were induced at four of these five sites in HEK 293T cells
(Supplemental Table 4). These results show that the discrepancy
between this study and Tsai et al. (2015) cannot be attributed to
the use of different cell lines and that Digenome-seq can capture
bona fide off-target sites missed by GUIDE-seq.
To reduce off-target effects, we replaced sgRNAswith versions
containing two extra guanines at the 5′ terminus (termed ggX20
sgRNAs) (Fig. 4A; Cho et al. 2014). These modified sgRNAs were
more specific than their respective GX19 sgRNAs by up to 598-
fold (Fig. 4B–G). It is of note that off-target indelswere not detected
above noise levels with the RNF2-specific ggX20 sgRNA (Fig. 4D).
Indel frequencies at off-target sites
The large number of NGS-validated (160) and NGS-invalidated
(144) off-target sites and indel frequencies determinedat these sites
allowedus to examine off-target effects in detail. A plot of thenum-
ber of mismatches versus the ratio of indel frequencies at off-target
relative to on-target sites showed that off-target siteswith up to two
mismatcheswere cleaved efficiently in cells (median indel frequen-
cy = 5.38%) and that those with three or more mismatches were
poorly cleaved (median indel frequency = 0.14% or lower, respec-
tively) (Fig. 5A). Indel frequencies at on-target sites were 60 ± 7%.
Interestingly, mismatches in the validated and invalidated sites
were almost evenly distributed in the PAM-distal and PAM-proxi-
mal regions. For both validated and invalidated sites with three
or more mismatches, the PAM-distal region was as important as
the seed region (Fig. 5B,C). Thus, indel frequencies at sites with
zero or onemismatch in the seed regionwere as lowas those at sites
with two or more mismatches.
In summary, we improved Digenome-seq to reduce the num-
ber of false-positive and false-negative sites by developing an in vi-
tro DNA cleavage scoring system and using sgRNAs transcribed
from a plasmid template rather than a synthetic oligonucleotide
duplex. We multiplexed Digenome-seq by digesting cell-free
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additional cleavage sites per sgRNA, on average, that had not been
captured by GUIDE-seq. Off-target indels were induced at many of
these sites in RGEN-transfected human cells. After carefully exam-
ining indel frequencies, mismatch numbers, and mismatch posi-
tions at hundreds of off-target sites, we conclude that both the
PAM-distal region and the PAM-proximal seed region are impor-
tant to RGEN specificities. We also noted that sites with two or
more mismatches in the seed region are much less likely to be
cleaved in vitro than those with no or one mismatch, regardless
of the total number of mismatches.
Discussion
Todisrupt a geneof interest usingRGENs, one should choose target
siteswithnoorfewoff-targeteffects.First,adesiredtargetsiteshould
have only a few or no off-target sites in the genome. Second, indel
frequencies at these off-target sites should bemuch lower than the
frequency at the on-target site. Our results suggest that a unique
site thathas fewer than13,000homologous siteswithup to sixmis-
matches in the human genome and that has no homologous sites
with up to two mismatches is desirable to minimize off-target ef-
fects. Out of 1715 targetable sites containing the 5′-NGG-3′ PAM
in the four genes examined in this study, 368 (21.5%) sites satisfy
these criteria (Supplemental Table 5). In addition, we present an
off-target score (Supplemental Table 6; Supplemental Scripts 3)
that accounts for numbers of potential off-target sites in the ge-
nome, fractions of these sites captured by Digenome-seq (Fig. 3B),
and median indel frequencies at these sites (Fig. 5A). One should
choose a low-score site to avoid or reduce off-target effects. A web-
basedcomputerprogramthat showsoff-target scores inageneof in-
terest is available at our website (www.rgenome.net/digenome).
A comprehensive analysis of genome-wide off-target sites us-
ing Digenome-seq and indel frequencies at these sites using target-
ed deep sequencing allowed us to define an off-target effect index
Table 1. Validation of off-target sites in human cells using next-generation sequencing
Digenome only Digenome and GUIDE GUIDE only
VEGFA1
Total captured sites 57 22 0
No. of NGS-tested sites 15 22 0
No. of validated sites 6 20 0
VEGFA2
Total captured sites 33 30 122
No. of NGS-tested sites 8 22 14
No. of validated sites 0 22 10
VEGFA3
Total captured sites 256 46 14
No. of NGS-tested sites 18 27 9
No. of validated sites 4 22 5
EMX1
Total captured sites 129 14 2
No. of NGS-tested sites 16 12 2
No. of validated sites 3 9 2
FANCF
Total captured sites 38 8 1
No. of NGS-tested sites 8 8 1
No. of validated sites 1 8 0
RNF2
Total captured sites 12 1 0
No. of NGS-tested sites 12 1 0
No. of validated sites 2 1 0
HEK293-1
Total captured sites 8 8 2
No. of NGS-tested sites 3 8 2
No. of validated sites 1 7 2
HEK293-2
Total captured sites 33 2 1
No. of NGS-tested sites 16 2 1
No. of validated sites 1 2 0
HEK293-3
Total captured sites 25 6 0
No. of NGS-tested sites 14 6 0
No. of vacated sites 2 6 0
HEK293-4
Total captured sites 112 104 26
No. of NGS-tested sites 17 24 16
No. of validated sites 1 19 4
Total
Total captured sites 703 241 168
No. of NGS-tested sites 127 132 45
No. of validated sites 21 116 23
Indel frequencies at off-target sites captured by Digenome-seq and GUIDE-seq were measured in human cells. Validated off-target sites were those with
indel frequencies above noise indel frequencies obtained in the absence of RGEN transfection. “Digenome only” and “GUIDE only” sites exclude
“Digenome and GUIDE” sites that were commonly identified by the two methods.
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(OTI), a ratio of the sum of indel frequencies at off-target sites to
the on-target indel frequency. The OTI for the RNF2-specific
GX19 or ggX20 sgRNA is 0.005 [(0.25% + 0.09%)/68%] or 0.0005
[(0.01%+ 0.01%)/44%], respectively, showing that these sgRNAs
are highly specific. The OTIs for two other GX19 sgRNAs, deter-
mined from our previous data (Kim et al. 2015), are 2.75 (HBB)
and 4.44 (VEGFA1) (Supplemental Note 1), showing that these
sgRNAs are not specific. Thus, OTIs can span more than three
orders of magnitude, depending on target sites and sgRNA
compositions.
To minimize or avoid RGEN off-target effects, we and others
have proposed various methods, which include dimeric Cas9 sys-
tems (paired Cas9 nickases [Mali et al. 2013a; Ran et al. 2013;
Cho et al. 2014] and dCas9-FokI [Guilinger et al. 2014; Tsai et al.
2014]), delivery of RGEN ribonucleoproteins (RNPs) (Kim et al.
2014; Ramakrishna et al. 2014; Zuris et al. 2015), and modified
guide RNAs (Cho et al. 2014; Fu et al. 2014). The dimeric systems
require two active sgRNAs and two adjacent PAMs, limiting target-
able sites.OurDigenome-seqdata suggest that the choiceof unique
or orthogonal target sites is also important and can be sufficient to
Figure 4. Indel frequencies determined using targeted deep sequencing at off-target sites. (A) Schematic of conventional sgRNAs (GX19 sgRNA) and
modified sgRNAs (ggX20 sgRNA). Indel frequencies at NGS-validated on- and off-target sites for the EMX1 (B), HEK293-3 (C), and RNF2 sgRNAs (D).
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reduce off-target indel frequencies below detection limits even
with a Cas9 monomer combined with a modified ggX20 sgRNA.
Truncated sgRNAs that target unique 17-nt sites that differ by at
least 2 or 3 nt from any other site in the genome can also be highly
specific, but such sites are much rarer than 20-nt full-length sites.
Digenome-seq differs fromother cell-basedmethods in that it
detects DNA cleavages in vitro, rather than in cells, using cell-free
genomicDNA. As a result, Digenome-seq is not limited by chroma-
tin, unlike other methods. Note that DSBs cannot be processed or
trimmed in vitro by endogenous DSB repair systems. This feature
favors pinpointing of in vitro cleavage sites and multiplexing
withDigenome-seq, becauseno computational search for sequenc-
es homologous to on-target sites is required. Furthermore, because
no PCR amplification steps are involved with Digenome-seq prior
to WGS, it is much simpler and easier to carry out than other
methods.
Pattanayak et al. (2013) examined in vitro specificities of Cas9-
sgRNA using partially randomized DNA substrate libraries contain-
ingapproximately1012 target sequencevariants, rather thanhuman
genomic DNA, and reported that five out of 49 sites cleaved in vitro
were validated in cells via targeted deep sequencing. This in vitro se-
lection approach is limited by two factors. First, randomized DNA
substrates cannot faithfully represent genomic DNA. A vast major-
ity of cleaved sequences donot exist in the genome. Second, poten-
tial off-target sites are determined by counting PCR amplicons
before and after in vitro cleavage and selection. The PCR step can
introduce biases, giving rise to false positives and negatives.
Although multiplex Digenome-seq was more comprehensive
and sensitive than GUIDE-seq and HTGTS, in general, it often
missed off-target sites captured by these methods. Monoplex
Digenome-seq using a high concentration of sgRNA may capture
some of these missing sites, although it is cost-inefficient to ana-
lyze many sgRNAs individually. We recommend using at least
two different methods, one in vitro method, namely, Digenome-
seq, and the other cell-basedmethod to profile genome-wide spec-
ificities of RGENs comprehensively.
Figure 5. Analysis of NGS-validated and NGS-invalidated off-target sites. Plots of relative indel frequencies (log scale) at off-target sites harboring the
number of mismatches indicated in the entire 20-nt sequence (A) or the 10-nt seed sequence (B,C). NGS-tested sites (A) were divided into two groups:
validated sites (B) and invalidated sites (C). NGS-validated sites and NGS-invalidated sites were those with indel frequencies above and below, respectively,
noise indel levels.
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Methods
Cas9 and in vitro sgRNA
Recombinant Cas9 protein was purchased from ToolGen. sgRNAs
were synthesized by in vitro transcription using T7 RNA poly-
merase as described previously (Kim et al. 2014). Briefly, sgRNA
templates were generated by annealing two complementary oligo-
nucleotides purchased from Macrogen. These oligonucleotides
were reverse-phase-purified using the vendor’s MOPC purification
method and quality-checked using MALDI-TOF. sgRNA templates
were incubated with T7 RNA polymerase in reaction buffer
(40 mM Tris-HCl, 6 mM MgCl2, 10 mM DTT, 10 mM NaCl,
2 mM spermidine, NTP, RNase inhibitor, at pH 7.9) for 8 h at
37°C. Transcribed sgRNAs were preincubated with DNase I to re-
move template DNA, and purified using PCR purification kits
(Macrogen).
Cell culture and transfection conditions
HeLa cells were cultured in DMEMmedia supplemented with 10%
FBS. HeLa cells (8 × 104) were cotransfected with the Cas9 expres-
sion plasmid (500 ng) and the sgRNA-encoding plasmid (500 ng)
using Lipofectamine 2000 (Life Technologies). HEK293T cells
were maintained in DMEM media supplemented with 10% FBS.
HEK293T cells (1 × 106) were electroporated with Cas9 expression
plasmid (5 µg) and the sgRNA-encoding plasmid (5 µg) using
Amaxa 4D Nucleofector. Genomic DNA was isolated with the
DNeasy tissue kit (Qiagen) according to the manufacturer’s in-
structions after 48 h.
In vitro cleavage of genomic DNA
Genomic DNA was purified from HAP1 cells (Carette et al. 2011)
with the DNeasy tissue kit (Qiagen). In vitro cleavage of genomic
DNA for Digenome-seq was carried out as described previously
(Kim et al. 2015). Briefly, Cas9 protein (40 µg) and 11 sgRNAs
(2.7 µg each) were preincubated at room temperature for 10 min
to form RNP complexes. Genomic DNA (8 µg) was incubated
with RNP complexes in a reaction buffer (100 mM NaCl, 50 mM
Tris-HCl, 10 mM MgCl2, 100 μg/mL BSA, at pH 7.9) for 8 h at
37°C. Digested genomic DNA was treated with RNase A (50 µg/
mL) to degrade sgRNAs and purified again with the DNeasy tissue
kit (Qiagen).
Whole-genome and Digenome sequencing
For whole-genome sequencing, Cas9-digested genomic DNA was
fragmented to 400–500 bp using Covaris (Thermo Fischer).
Fragmented genomic DNA (1 µg) was ligated with adaptors using
TruSeqDNA library prep kit. Libraries were subjected toWGSusing
an Illumina HiSeq X Ten sequencer at Macrogen. WGS is per-
formed at a sequencing depth of 30× to 40×. We used Isaac aligner
to align the sequence file to the human reference genome
hg19 (Raczy et al. 2013) or GRCh38 (Cunningham et al. 2015)
with the followingmapping program and parameters: base quality
cutoff, 15; keep duplicate reads, yes; variable read length sup-
port, yes; realign gaps, no; and adaptor clipping, yes (adaptor
AGATCGGAAGAGC∗,∗GCTCTTCCGATCT). DNA cleavage sites
were identified computationally using a cleavage scoring system
described in Supplemental Figure 1. The resulting multiplex
Digenome-captured sites were classified into 11 groups by edit dis-
tance (Zorita et al. 2015). The computer programs used for identi-
fication of in vitro RGEN cleavage sites and classification of these
Digenome-captured sites by edit distance are available at our
website (www.rgenome.net/digenome). Note that no genomic
DNA isolated from CRISPR-Cas9–transfected cells was used for
Digenome-seq in this study. It is unnecessary to carry outWGS us-
ing Cas9-undigested genomic DNA in future studies because there
were essentially no false-positive sites with cleavage scores above
the cutoff value of 2.5 as shown in Figure 1A.
Targeted deep sequencing
On-target and potential off-target candidate sites were amplified
using Phusion polymerase (New England Biolabs). PCR amplicons
were denatured by NaOH and subjected to paired-end sequencing
using Illumina MiSeq. Indel frequencies were calculated as de-
scribed previously (Kim et al. 2014).
Data access
The deep sequencing data from this study have been submitted to
the NCBI Sequence Read Archive (SRA; http://www.ncbi.nlm.nih.
gov/sra/) under accession number SRP067307.
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